Analysis of multipotent mesenchymal stromal cells used for acute graft-versus-host disease prophylaxis

European Journal of Haematology

Volumn 96, Issue 4, 2016, Pages 425-434

  Kuzmina, Larisa A ^a   Petinati, Nataliya A ^a   Shipounova, Irina N ^a   Sats, Natalia V ^a   Bigildeev, Alexey E ^a   Zezina, Ekaterina A ^b   Popova, Maria D ^b   Drize, Nina J ^a   Parovichnikova, Elena N ^a   Savchenko, Valery G ^a  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Acute graft versus host disease prophylaxis; Colony forming unit fibroblast; Gene expression; Mesenchymal stromal cell

Indexed keywords

CSF1 PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; PDGFRB PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; COLONY STIMULATING FACTOR RECEPTOR; FGFR1 PROTEIN, HUMAN; FGFR2 PROTEIN, HUMAN; MYELOABLATIVE AGENT; PDGFRB PROTEIN, HUMAN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGE; AGEISM; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CLINICAL ARTICLE; COLONY FORMING UNIT; COLONY FORMING UNIT F; CONTROLLED STUDY; DONOR; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MESENCHYMAL STROMA CELL; OVERALL SURVIVAL; PRIMARY CULTURE; PRIORITY JOURNAL; ADOLESCENT; ALLOTRANSPLANTATION; CYTOLOGY; GENE EXPRESSION; GENETICS; GRAFT VS HOST DISEASE; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

ADOLESCENT; ADULT; FEMALE; GENE EXPRESSION; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; PPAR GAMMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84937597698     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12613     Document Type: Article

References (50)

1. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect 1967;62:21-78.
2. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007;25:139-70.
3. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56.
4. ™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011;17:534-41.
5. Fong TA, Mosmann TR. Alloreactive murine CD8 + T cell clones secrete the Th1 pattern of cytokines. J Immunol 1990;144:1744-52.
6. Visentainer JEL, Lieber SR, Persoli LBL, Vigorito AC, Aranha FJP, de Brito Eid KA, Oliveira GB, Miranda ECM, de Souza CA. Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation. Exp Hematol 2003;31:1044-50.
7. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 1999;5:347-56.
8. Introna M, Rambaldi A. Mesenchymal stromal cells for prevention and treatment of graft-versus-host disease: successes and hurdles. Curr Opin Organ Transplant 2015;20:72-8.
9. Kim N, Im K-I, Lim J-Y, Jeon E-J, Nam Y-S, Kim E-J, Cho S-G. Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice. Ann Hematol 2013;92:1295-308.
10. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000;28:875-84.
11. Gazdic M, Volarevic V, Arsenijevic N, Stojkovic M. Mesenchymal stem cells: a friend or foe in immune-mediated diseases. Stem Cell Rev 2015;11:280-7.
12. Reinisch A, Etchart N, Thomas D, et al. Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood 2014;125:249-60.
13. Samsonraj RM, Rai B, Sathiyanathan P, Puan KJ, Rötzschke O, Hui JH, Raghunath M, Stanton LW, Nurcombe V, Cool SM. Establishing criteria for human mesenchymal stem cell potency. Stem Cells 2015;33:1878-91.
14. Jones BJ, McTaggart SJ. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol 2008;36:733-41.
15. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-22.
16. ® allogeneic cells for immunomodulatory therapy: clinical progress and pre-clinical challenges in prophylaxis for graft versus host disease. Front Immunol 2012;3:345.
17. Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunol Cell Biol 2013;91:40-51.
18. Maziarz RT, Devos T, Bachier CR, et al. Single and multiple dose multistem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trial. Biol Blood Marrow Transplant 2015;21:720-8.
19. Ringdén O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81:1390-7.
20. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-41.
21. Kuzmina LA, Petinati Na, Parovichnikova EN, et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host disease - a phase II study. Stem Cells Int 2012;2012:968213.
22. Samuelsson H, Ringdén O, Lönnies H, Le Blanc K. Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. Cytotherapy 2009;11:129-36.
23. Prockop DJ, Brenner M, Fibbe WE, Horwitz E, Le Blanc K, Phinney DG, Simmons PJ, Sensebe L, Keating A. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010;12:576-8.
24. Von Bahr L, Sundberg B, Lönnies L, et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012;18:557-64.
25. Schu S, Nosov M, O'Flynn L, Shaw G, Treacy O, Barry F, Murphy M, O'Brien T, Ritter T. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 2012;16:2094-103.
26. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304.
27. Lange C, Cakiroglu F, Spiess A, Cappallo-obermann H, Dierlamm J, Zander AR. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. J Cell Physiol 2007;8904:18-26.
28. Svinareva DA, Petrova TV, Shipunova IN, Momotiuk KS, Mikhaĭlova EA, Drize NI. The study of parameters of mesenchymal stromal cells differentiation in donors and patients with aplastic anemia. Ter Arkh 2009;81:66-70.
29. Bigildeev AE, Zezina EA, Shipounova IN, Drize NJ. Interleukin-1 beta enhances human multipotent mesenchymal stromal cell proliferative potential and their ability to maintain hematopoietic precursor cells. Cytokine 2015;71:246-54.
30. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
31. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008;3:1101-8.
32. Appelbaum FR. The current status of hematopoietic cell transplantation. Annu Rev Med 2003;54:491-512.
33. Colter DC, Sekiya I, Prockop DJ. Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci USA 2001;98:7841-5.
34. Bigildeev AE, Zhironkina OA, Shipounova IN, Sats NV, Kotyashova SY, Drize NI. Clonal composition of human multipotent mesenchymal stromal cells. Exp Hematol 2012;40:847-56.e4.
35. Menssen A, Häupl T, Sittinger M, Delorme B, Charbord P, Ringe J. Differential gene expression profiling of human bone marrow-derived mesenchymal stem cells during adipogenic development. BMC Genomics 2011;12:461.
36. Jiang SS, Chen C-H, Tseng K-Y, Tsai F-Y, Wang MJ, Chang I-S, Lin J-L, Lin S. Gene expression profiling suggests a pathological role of human bone marrow-derived mesenchymal stem cells in aging-related skeletal diseases. Aging (Albany NY) 2011;3:672-84.
37. Tuljapurkar SR, McGuire TR, Brusnahan SK, Jackson JD, Garvin KL, Kessinger MA, Lane JT, O' Kane BJ, Sharp JG. Changes in human bone marrow fat content associated with changes in hematopoietic stem cell numbers and cytokine levels with aging. J Anat 2011;219:574-81.
38. Jiang Y, Mishima H, Sakai S, Liu Y-K, Ohyabu Y, Uemura T. Gene expression analysis of major lineage-defining factors in human bone marrow cells: effect of aging, gender, and age-related disorders. J Orthop Res 2008;26:910-7.
39. Gieseke F, Böhringer J, Bussolari R, Dominici M, Handgretinger R, Müller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 2010;116:3770-9.
40. Rosengren S, Corr M, Boyle DL. Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes. Arthritis Res Ther 2010;12:R65.
41. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117:3720-32.
42. Liu S, Ginestier C, Ou SJ, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011;71:614-24.
43. Yan B, Chen G, Saigal K, Yang X, Jensen ST, Van Waes C, Stoeckert CJ, Chen Z. Systems biology-defined NF-kappaB regulons, interacting signal pathways and networks are implicated in the malignant phenotype of head and neck cancer cell lines differing in p53 status. Genome Biol 2008;9:R53.
44. Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-21.
45. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, Puccetti P. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002;9:1069-77.
46. Tu Z, Li Q, Bu H, Lin F. Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells Dev 2010;19:1803-9.
47. Landin-Wilhelmsen K, Lundberg P-A, Lappas G, Wilhelmsen L. Insulin-like growth factor I levels in healthy adults. Horm Res 2004;62(Suppl 1):8-16.
48. Mayack SR, Shadrach JL, Kim FS, Wagers AJ. Systemic signals regulate ageing and rejuvenation of blood stem cell niches. Nature 2010;463:495-500.
49. Sroga GE, Wu P-C, Vashishth D. Insulin-like growth factor 1, glycation and bone fragility: implications for fracture resistance of bone. PLoS ONE 2015;10:e0117046.
50. Shipounova IN, Petinati NA, Bigildeev AE, Zezina EA, Drize NI, Kuzmina LA, Parovichnikova EN, Savchenko VG. Analysis of results of acute graft-versus-host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry (Mosc) 2014;79:1363-70.